Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study

BACKGROUND: Tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. This phase 3 randomized, double-blind study evaluated pexidartinib, a CSF1 receptor inhibitor, in patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Tap, William D., Gelderblom, Hans, Palmerini, Emanuela, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Ryan, Christopher W., Thomas, David M., Peterfy, Charles, Healey, John H., van de Sande, Michiel, Gelhorn, Heather L., Shuster, Dale E., Wang, Qiang, Yver, Antoine, Hsu, Henry H., Lin, Paul S., Tong-Starksen, Sandra, Stacchiotti, Silvia, Wagner, Andrew J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6860022/
https://ncbi.nlm.nih.gov/pubmed/31229240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(19)30764-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados